The federal government has terminated more than 100 independent scientific advisory committees across multiple research agencies following a February 2025 executive order aimed at shrinking the national bureaucracy. President Donald Trump and his administration have initiated historic reductions in the federal scientific workforce, coupling tens of thousands of personnel cuts with the cancellation of thousands of active research grants.
An analysis published by Nature reveals that the Department of Health and Human Services, which encompasses the National Institutes of Health, disbanded 77 advisory boards in 2025 alone. This wave of closures represents more than one-quarter of the agency’s total expert panels and marks a stark departure from the previous fiscal year, when the department terminated just two committees.
Historical data governed by the Federal Advisory Committee Act indicates that annual terminations at the Department of Health and Human Services have exceeded ten only once since comprehensive public tracking began in 1997. The sweeping reductions extend well beyond biomedical research, heavily impacting the National Science Foundation, the Department of Energy, and the National Aeronautics and Space Administration, where more than half of all advisory boards were dissolved.
These dismantled panels previously relied on university scientists and independent experts to assess national research priorities in areas ranging from high-energy physics to planetary science. Within the medical and public health sectors, the eliminated committees had been actively advising federal officials on critical clinical issues including organ transplantation protocols, HIV prevention strategies, and genomic research frameworks.
Beyond outright terminations, federal agencies have fundamentally altered the operational transparency of the remaining advisory bodies by drastically reducing the number of meetings open to public observation and scientific scrutiny. Open sessions at the Department of Health and Human Services plummeted from a ten-year average of 255 annual meetings to just 91 in 2025.
The downsizing of federal advisory committees is even starker than the official termination numbers suggest, as several surviving panels are meeting far less frequently than in typical years. Some prominent groups, including those that historically advised the leadership of the National Institutes of Health, have not convened a single meeting since the current administration took office.
In a parallel administrative action executed last week, the White House abruptly dismissed all 22 members of the board responsible for advising and overseeing the National Science Foundation. A White House spokesperson justified the mass dismissal by citing the 2021 Supreme Court case United States v. Arthrex, Inc., arguing the ruling raised constitutional questions regarding the board’s unconfirmed membership structure.
The administration intends to update the underlying statutory framework so the oversight board can perform its duties exactly as Congress originally intended, according to the official statement. Federal officials have also intervened in the composition of high-profile advisory bodies like the Advisory Committee on Immunization Practices, removing dissenting voices and installing members who align with the administration’s stance on vaccines.
The federal government further bypassed standard scientific consensus by issuing new national dietary guidelines in January without any input from the Dietary Guidelines Advisory Committee. This panel was explicitly tasked with reviewing current nutritional science to inform federal recommendations, and its exclusion sparked immediate controversy among nutrition experts who argued the revisions ignored established clinical evidence.
Former federal science officials argue that dismantling these structured committees severs a vital conduit for independent expertise and degrades the quality of evidence-based policymaking. “The fewer of these advisory panels there are, it inherently diminishes the transparency of the entire operation,” says Carrie Wolinetz, former head of the science-policy office at the National Institutes of Health.
Researchers emphasize that these panels historically functioned as a crucial bidirectional communication channel between isolated federal agencies and the broader academic community. “That two-way street, I think, was invaluable,” says Juan Meza, an applied mathematician at the University of California, Merced, who previously served on two now-disbanded panels at the National Science Foundation and the Department of Energy.
Some scientists and agency employees concede there can be sound administrative reasons to streamline these committees by combining overlapping groups or eliminating those that have fulfilled their original statutory mandates. But many biomedical researchers counter that the sheer scale of the administration’s current efforts greatly reduces both the volume and the clinical quality of advice the government receives.
White House spokesperson Kush Desai asserts that the federal government’s redundant advisory committees failed to meaningfully inform public policy during the COVID-19 pandemic, providing a direct justification for the closures. He says the administration is prioritizing rigorous clinical data over administrative waste.
“The Trump Administration is eliminating the bureaucratic bloat and taking a hands-on approach to ensure that policymaking is driven by Gold Standard Science.”
Clinical advocates argue that the aggressive consolidation disproportionately harms vulnerable patient populations who rely on formal advisory committees to elevate their specific medical needs to federal funding agencies. Ian Simon, former head of the recently eliminated Office of Long COVID Research and Practice, notes that a disbanded long COVID committee was uniquely designed to give patients a voice equal to those of physicians and researchers.
Simon warns that the abrupt dissolution of specialized clinical panels leaves millions of patients navigating a federal research environment devoid of dedicated formalized advocacy. He emphasizes that the closures directly threaten ongoing clinical investigations into chronic infectious conditions.
“It is very hard to see how these actions will advance the work that’s needed to understand long COVID and other infectious chronic conditions.”
As federal agencies continue to reorganize their remaining scientific infrastructure, independent researchers will closely monitor how the absence of external oversight impacts future funding allocations for complex genomic and biomedical research. The scientific community now faces a significant challenge in ensuring that national public health directives remain grounded in rigorous, peer-reviewed data despite the structural collapse of traditional advisory channels.
